- In March 2023, the orthobiologics market concluded on a positive note despite challenges like staffing shortages, supply chain constraints, and inflation. Anticipated growth in 2023 is expected to be driven by the resurgence of elective procedures and strategic initiatives by key industry players. Key focus areas include reshaping the competitive landscape, advancements in osteobiologics, and shifts in the U.S. bone replacement and sports medicine markets
- In September 2024, Temple OrthoBiologics launched with a mission to revolutionize sports medicine by preventing scar tissue formation—a long-standing challenge in orthopedic recovery. Their flagship product, TX-33, is an intra-articular treatment combining advanced biomaterials and targeted drug delivery, aimed at enhancing tissue repair post-injury or surgery
- In August 2023, the American Academy of Orthopaedic Surgeons (AAOS) highlighted the potential of orthobiologics—treatments utilizing biological substances like platelet-rich plasma—to offer less invasive options for musculoskeletal conditions such as osteoarthritis and tendinopathies. These therapies aim to alleviate pain, reduce inflammation, and enhance healing, potentially delaying or avoiding the need for surgery
- In February 2023, projections indicated that the global orthobiologics market, valued at approximately USD 6.5 billion in 2022, is expected to reach USD 10.3 billion by 2030, growing at a CAGR of 5.9%. This growth is driven by increased product launches, rising prevalence of orthopedic conditions, and advancements in biologic materials. Bone allografts are anticipated to maintain a leading market share due to their effectiveness in procedures like spinal fusion. North America is projected to remain the dominant regional market, supported by a strong presence of key industry players and favorable reimbursement policies
